FindTrial
Sign In

Multiparametric MRI assessment of the malignancy and prognosis of prostate cancer

Multiparametric MRI assessment of the malignancy and prognosis of prostate cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300076464
Enrollment
Unknown
Registered
2023-10-09
Start date
2022-04-01
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Gold Standard:Pathological results of puncture or surgery
Index test:Magnetic resonance elastography (MRE) combined with traditional multi-parameter magnetic resonance imaging

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. patients suspected or diagnosed with prostate cancer; 2. systemic biopsy or prostatectomy was suggested by clinician; 3. no prior therapy .

Exclusion criteria

Exclusion criteria: 1. confirmed prostate cancer with bone metastasis; 2. patient with contraindication of MRI examination, including metal implants in the body, claustrophobia, etc. 3. patient with severe cardiopulmonary dysfunction.

Design outcomes

Primary

MeasureTime frame
Gleason score;Lymph node metastasis;Bone metastasis;Recurrence;PI-RADS score;Stiffness;Accuracy;Sensitivity;Specificity;Odds ratio;Hazard ratio;—

Countries

China

Contacts

Public ContactSong Bin

West China Hospital, Sichuan University

cjr.songbin@vip.163.com+86 189 8060 1592

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026